Chapter 1. Executive Summary
1.1. Market Snapshot
1.2. Global & Segmental Market Estimates & Forecasts, 2019-2029 (USD Billion)
1.2.1. Sarcoma Drugs Market, by Region, 2019-2029 (USD Billion)
1.2.2. Sarcoma Drugs Market, by Treatment Type, 2019-2029 (USD Billion)
1.3. Key Trends
1.4. Estimation Methodology
1.5. Research Assumption
Chapter 2. Global Sarcoma Drugs Market Definition and Scope
2.1. Objective of the Study
2.2. Market Definition & Scope
2.2.1. Scope of the Study
2.2.2. Industry Evolution
2.3. Years Considered for the Study
2.4. Currency Conversion Rates
Chapter 3. Global Sarcoma Drugs Market Dynamics
3.1. Sarcoma Drugs Market Impact Analysis (2019-2029)
3.1.1. Market Drivers
3.1.1.1. Rise in the prevalence of soft tissue sarcoma
3.1.1.2. Increasing number of product approval for new sarcoma drugs
3.1.2. Market Challenges
3.1.2.1. High Cost of Sarcoma Drugs
3.1.3. Market Opportunities
3.1.3.1. Rising investment for the research and development of sarcoma drugs
Chapter 4. Global Sarcoma Drugs Market Industry Analysis
4.1. Porter’s 5 Force Model
4.1.1. Bargaining Power of Suppliers
4.1.2. Bargaining Power of Buyers
4.1.3. Threat of New Entrants
4.1.4. Threat of Substitutes
4.1.5. Competitive Rivalry
4.2. Futuristic Approach to Porter’s 5 Force Model (2019-2029)
4.3. PEST Analysis
4.3.1. Political
4.3.2. Economical
4.3.3. Social
4.3.4. Technological
4.4. Top investment opportunity
4.5. Top winning strategies
4.6. Industry Experts Prospective
4.7. Analyst Recommendation & Conclusion
Chapter 5. Risk Assessment: COVID-19 Impact
5.1. Assessment of the overall impact of COVID-19 on the industry
5.2. Pre COVID-19 and post COVID-19 Market scenario
Chapter 6. Global Sarcoma Drugs Market, by Treatment Type
6.1. Market Snapshot
6.2. Global Sarcoma Drugs Market by Treatment Type, Performance – Potential Analysis
6.3. Global Sarcoma Drugs Market Estimates & Forecasts by Treatment Type 2019-2029 (USD Billion)
6.4. Sarcoma Drugs Market, Sub Segment Analysis
6.4.1. Chemotherapy
6.4.2. Targeted Therapy
Chapter 7. Global Sarcoma Drugs Market, Regional Analysis
7.1. Sarcoma Drugs Market, Regional Market Snapshot
7.2. North America Sarcoma Drugs Market
7.2.1. U.S. Sarcoma Drugs Market
7.2.1.1. Treatment Type breakdown estimates & forecasts, 2019-2029
7.2.2. Canada Sarcoma Drugs Market
7.3. Europe Sarcoma Drugs Market Snapshot
7.3.1. U.K. Sarcoma Drugs Market
7.3.2. Germany Sarcoma Drugs Market
7.3.3. France Sarcoma Drugs Market
7.3.4. Spain Sarcoma Drugs Market
7.3.5. Italy Sarcoma Drugs Market
7.3.6. Rest of Europe Sarcoma Drugs Market
7.4. Asia-Pacific Sarcoma Drugs Market Snapshot
7.4.1. China Sarcoma Drugs Market
7.4.2. India Sarcoma Drugs Market
7.4.3. Japan Sarcoma Drugs Market
7.4.4. Australia Sarcoma Drugs Market
7.4.5. South Korea Sarcoma Drugs Market
7.4.6. Rest of Asia Pacific Sarcoma Drugs Market
7.5. Latin America Sarcoma Drugs Market Snapshot
7.5.1. Brazil Sarcoma Drugs Market
7.5.2. Mexico Sarcoma Drugs Market
7.5.3. Rest of Latin America Sarcoma Drugs Market
7.6. Rest of The World Sarcoma Drugs Market
Chapter 8. Competitive Intelligence
8.1. Top Market Strategies
8.2. Company Profiles
8.2.1. Baxter Healthcare Corporation
8.2.1.1. Key Information
8.2.1.2. Overview
8.2.1.3. Financial (Subject to Data Availability)
8.2.1.4. Product Summary
8.2.1.5. Recent Developments
8.2.2. Bristol-Myers Squibb Company
8.2.3. Daiichi Sankyo Company Limited
8.2.4. AgonOX, Inc.
8.2.5. Eisai Co., Ltd.
8.2.6. GlaxoSmithKline, plc.
8.2.7. Hoffmann-La Roche AG.
8.2.8. Johnson and Johnson
8.2.9. MERCK & CO., Inc
8.2.10. Novartis AG
Chapter 9. Research Process
9.1. Research Process
9.1.1. Data Mining
9.1.2. Analysis
9.1.3. Market Estimation
9.1.4. Validation
9.1.5. Publishing
9.2. Research Attributes
9.3. Research Assumption
*** 免責事項 ***
https://www.globalresearch.co.jp/disclaimer/